Metropolitan Life Insurance Company (MetLife)’s Harvard Bioscience HBIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-234	Closed	-$9.91K	–	916
2024 Q1	$9.91K	Buy	234 +18	+8%	+$809	﹤0.01%	2134
2023 Q4	$11.5K	Hold	216	–	–	﹤0.01%	2135
2023 Q3	$9.27K	Hold	216	–	–	﹤0.01%	2241
2023 Q2	$11.8K	Buy	+216	New	+$11.9K	﹤0.01%	2214
2022 Q2	–	Sell	-277	Closed	-$17.2K	–	2395
2022 Q1	$17.2K	Sell	277 -862	-76%	-$51K	﹤0.01%	2155
2021 Q4	$80.3K	Buy	1,139 +17	+2%	+$1.21K	﹤0.01%	2589
2021 Q3	$78.3K	Buy	+1,122	New	+$89.3K	﹤0.01%	2650

Other funds holding HBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s HBIO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Harvard Bioscience (HBIO) in Q2 2024, closing a stake of 234 shares — an estimated $9.91K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in HBIO in Q3 2021 and held it in 7 quarters. The position peaked at $80.3K in Q4 2021. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Harvard Bioscience position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 234 Harvard Bioscience shares in Q2 2024, an estimated $9.91K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Harvard Bioscience in Q3 2021 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Harvard Bioscience position peaked at $80.3K in Q4 2021.
100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.